Welcome to our dedicated page for Optimi Health news (Ticker: OPTHF), a resource for investors and traders seeking the latest updates and insights on Optimi Health stock.
Optimi Health Corp. reports on its role as a commercial-stage pharmaceutical manufacturer of regulated botanical wellness drug products, including GMP-manufactured MDMA capsules and natural botanical research compound capsules. Company updates commonly cover Health Canada-licensed production, export permits, finished dosage forms, and supply into regulated medical access pathways.
Recurring news themes include shipments and clinical use under Australia’s Authorised Prescriber Scheme, products supplied for PTSD and treatment-resistant depression, access through Canada’s Special Access Program, and initiatives to expand manufacturing capability to ibogaine. Optimi also reports capital-market actions, financing documents, investor presentations, and regulatory readiness tied to its cross-border commercial strategy.
Catcher Investments acquired 3,000 unsecured convertible debentures of Optimi Health Corp on July 25, 2025, for a total of CAD 3,000,000 in a non-brokered private placement.
The debentures bear 15.0% annual interest payable quarterly, mature in 12 months (extendable to 24 months at the acquiror's option), and are convertible into common shares at a conversion price of CAD 0.15. Accrued interest may be paid in cash or common shares (issued at the most recent CSE closing price if converted).
Before and after the investment the acquiror directly or indirectly holds 8,237,501 common shares (~8.52% undiluted) and, including warrants and options, represents ~10.08% on a partially diluted basis.
Optimi Health (OTCQX: OPTHF) announced it passed a Health Canada Drug Establishment Licence inspection with no critical observations, receiving a GMP-compliant rating to fabricate, label, package, distribute and wholesale pharmaceutical-grade psychedelic finished drug products and APIs.
The Company stated its MDMA capsules for PTSD and psilocybin capsules for treatment-resistant depression are being prescribed in Australia under the Authorized Prescriber Scheme. Optimi also signed a market‑making agreement with Independent Trading Group on Sept 30, 2025, subject to CSE approval, at CDN$6,500 per month with automatic one‑month renewals.
Optimi Health (OTCQX: OPTHF) announced its 5mg naturally‑derived psilocybin capsules were selected for inclusion in Medibank’s psychotherapy program, an AUD $10M insurance‑backed initiative now expanded to reimburse psilocybin‑assisted therapy for treatment‑resistant depression (TRD).
Medibank serves ~4.2 million customers; program services will be delivered by Emyria’s Empax Centre in Perth and Optimi’s product will be supplied via its exclusive distributor, Mind Medicine Australia. Optimi’s capsules have been available in Australia since September 3, 2025. The program is part of a broader AUD $50M five‑year Medibank commitment to mental‑health innovation.
Optimi Health Corp. (OTCQX: OPTHF), a Canadian manufacturer of MDMA and naturally-derived psilocybin, has publicly filed a registration statement with the SEC for a proposed U.S. IPO. The company has applied to list its common shares on the Nasdaq Capital Market under the symbol "OPTH".
While the specific number of shares and price range are yet to be determined, Titan Partners Group will serve as the sole book-running manager for the offering. The registration statement (File Number: 333-290086) has been filed but is not yet effective, and securities cannot be sold until it becomes effective.
Optimi Health (OTCQX: OPTHF) has launched natural psilocybin capsules in Australia for treating Treatment-Resistant Depression (TRD) under the Authorised Prescriber Scheme. The company has shipped 1,000 capsules containing 5mg of standardized naturally-derived psilocybin, manufactured at their GMP-licensed facility in British Columbia.
The launch follows Optimi's successful introduction of MDMA sales for PTSD treatment in Australia in October 2024. Mind Medicine Australia, Optimi's commercial partner, will manage distribution and patient coordination through Australian clinics and hospitals, while collecting patient-reported outcome data to build comprehensive real-world evidence for psilocybin treatment.
Optimi Health (OTCQX: OPTHF), a GMP-certified MDMA and psilocybin manufacturer, has announced two significant updates. First, the company has engaged MZ Investor Relations for strategic capital markets support at US$9,000-13,500 monthly, granting them 1.9 million stock options with varying exercise prices and vesting schedules.
On the manufacturing front, Optimi has achieved a milestone by completing production of over 3,000 GMP doses of 5mg natural psilocybin extract capsules. These will be used to treat Treatment-Resistant Depression patients in Australia and supply upcoming Phase 2 clinical trials globally. The company offers GMP-certified MDMA capsules (40mg and 60mg), psilocybin capsules, and APIs to licensed distributors and pharmaceutical companies.
Cathay Visions Enterprises Ltd. has acquired 450 unsecured convertible debentures of Optimi Health Corp. (OTC:OPTHF) at CAD$1,000 per debenture, totaling a CAD$450,000 investment. The debentures feature a 15% annual interest rate, payable quarterly in cash, with a 12-month maturity that can be extended to 24 months.
The debentures are convertible into common shares at $0.15 per share. Prior to this acquisition, Cathay owned 11,875,566 common shares (12.29% ownership). Following the acquisition, Cathay now controls 11,875,566 shares, 533,333 warrants, and 450,000 stock options, representing 12.29% undiluted and 13.71% partially diluted ownership.
["Debentures offer attractive 15% annual interest rate", "Flexibility to convert debentures to equity at $0.15 per share", "Option to extend maturity from 12 to 24 months"]Optimi Health (OTCQX: OPTHF), a Canadian manufacturer of GMP-grade MDMA and natural psilocybin, has announced a CAD$3.45 million convertible debenture financing and the extension of a secured term loan. The convertible debentures, priced at CAD$1,000 each, will bear a 15% annual interest rate and are convertible into common shares at $0.15 per share.
The company has also extended its CAD$1 million secured term loan to April 30, 2026, which carries a 7.5% annual interest rate. As part of the loan extension, Optimi issued 400,000 warrants exercisable at $0.25 per share for two years.
The convertible financing involves two insiders: CEO Dane Stevens and Board Chair JJ Wilson, who will hold 12.29% and 8.52% of the company respectively post-transaction.
Optimi Health (OPTHF) has completed its largest international MDMA export to Australia, delivering 1,000 GMP-certified capsules for PTSD treatment. The shipment, conducted with Mind Medicine Australia, includes both 40mg and 60mg strength capsules and received approval from Australia's Therapeutic Goods Administration (TGA) and Health Canada.
In a significant development, the Australian Department of Veterans' Affairs (DVA) has announced it will fund MDMA-assisted therapy for veterans diagnosed with PTSD, marking the first time a federal agency in Australia has committed to reimbursing psychedelic-assisted treatment. The capsules will be distributed through authorized pharmacy networks and clinics across Australia under Optimi's Drug Establishment Licence (DEL).
Optimi Health (OPTHF) has received its U.S. FDA Establishment Identifier (FEI) number, marking a significant regulatory milestone that enables the company to supply GMP-certified MDMA and psilocybin to authorized entities in the United States. The registration positions Optimi as an FDA-recognized pharmaceutical manufacturer capable of producing both active ingredients and finished drug products.
Operating from its Canada-based facility with a Health Canada Drug Establishment License (DEL), Optimi can now engage in FDA filings and participate in the U.S. pharmaceutical supply chain. The company's capabilities include manufacturing pharmaceutical-grade MDMA and psilocybin in both API form and encapsulated drug products. This development is particularly timely as 25 U.S. states have considered psychedelic legislation through more than 74 bills.